NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$131.67
+0.34% today
Updated 2026-04-30
Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
—
52W range
$108 – $160
Volume
1.1M
Neurocrine Biosciences Inc (NBIX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-5.2%
Last 4 quarters
Revenue YoY growth
+28.3%
Most recent quarter
EPS YoY growth
+11.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-10.6%
2026-02-11
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $1.88 | +1.1% | $137.65 | $123.10 | -10.6% |
| 2025-10-30 | $2.17 | +3.8% | $138.02 | $143.21 | +3.8% |
| 2025-07-30 | $1.65 | +10.0% | $134.19 | $128.23 | -4.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.86 | $1.88 | +1.1% | $805.50M | +28.3% |
| 2025-09-30 | $2.09 | $2.17 | +3.8% | $794.90M | +27.8% |
| 2025-06-30 | $1.50 | $1.65 | +10.0% | $687.50M | +16.5% |
| 2025-03-31 | $1.09 | $0.70 | -35.8% | $572.60M | +11.1% |
| 2024-12-31 | $1.93 | $1.69 | -12.4% | $627.70M | +21.8% |
| 2024-09-30 | $1.82 | $1.81 | -0.5% | $622.10M | +24.7% |
| 2024-06-30 | $1.05 | $0.63 | -40.0% | $590.20M | +30.4% |
| 2024-03-31 | $1.01 | $0.42 | -58.4% | $515.30M | — |
| 2023-12-31 | $1.15 | $1.44 | +25.2% | $515.20M | — |
| 2023-09-30 | $0.97 | $0.82 | -15.5% | $498.80M | — |
| 2023-06-30 | $0.78 | $0.95 | +21.8% | $452.70M | — |
Frequently asked questions
Has Neurocrine Biosciences Inc beaten earnings estimates?
Neurocrine Biosciences Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -5.2% over the last 4 quarters.
How does NBIX stock react to earnings?
NBIX stock has moved an average of -3.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Neurocrine Biosciences Inc's revenue growth rate?
Neurocrine Biosciences Inc reported year-over-year revenue growth of +28.3% in its most recent quarter, with EPS growing +11.2% year-over-year.